What do you notice from these seven metrics (or indicators) about the prosperity and quality of life of the United States, compared to other countries? What do you wonder? By The Learning ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback